From Tasks to Intelligent Operations: How Pharma Organizations Can Build Custom AI Workflow
From Tasks to Intelligent Operations: How Pharma Organizations Can Build Custom AI Workflows
Why the next generation of pharma technology will be built around workflows
Pharmaceutical organizations do not suffer from a shortage of software.
They suffer from fragmentation.
Clinical development may operate across clinical trial systems, safety platforms, regulatory repositories, scientific literature, document management systems and data warehouses. Medical Affairs has its own evidence sources and engagement processes. Commercial teams depend on market intelligence, CRM platforms and analytics. Manufacturing and quality operate through another collection of highly controlled systems.
Each application may perform its individual function well.
The problem begins when work has to move across systems, teams, data sources and decisions.
A medical information request may require evidence retrieval, document interpretation, medical review, compliance checks, response generation and approval.
A pharmacovigilance process may require case intake, information extraction, seriousness assessment, duplicate checking, medical review, coding, narrative generation, quality control and regulatory reporting.
A clinical-development process may involve protocol information, trial data, literature, investigator information, regulatory requirements and internal review.
These are not single AI tasks.
They are workflows.
This is where an agentic Platform-as-a-Service such as Anxya Health changes the model.
Instead of asking an organization to replace every existing enterprise system, the objective is to orchestrate the work that happens across those systems.
Anxya describes this architecture as five interconnected layers:
Data → Connectors → Workflows → APIs → Agents
Together, these layers create an orchestration model in which enterprise data can be securely connected to multi-agent processes and ultimately delivered through the interface most appropriate for the user.
The five-layer orchestration model
Think of the five layers as an intelligent operating chain.
1. Data — the foundation
Everything starts with approved and governed data.
For a pharmaceutical organization, this might include:
- Clinical trial data
- Scientific publications
- Regulatory documents
- Product information
- Safety data
- Standard operating procedures
- Medical literature
- Label information
- Quality documentation
- Manufacturing information
- Commercial intelligence
- Internal policies
- Approved knowledge repositories
The important principle is that AI should not simply have unrestricted access to everything.
Organizations need to determine:
What data can be used? By whom? For which workflow? Under which conditions?
The data layer therefore becomes the foundation for controlled AI operations.
2. Connectors — connecting the enterprise
The second layer connects the AI environment to the systems where pharmaceutical organizations already work.
Instead of replacing the enterprise technology landscape, orchestration can sit across it.
For example, an organization could connect appropriate sources from:
- Clinical systems
- Safety systems
- Document repositories
- CRM
- Data warehouses
- Research databases
- Regulatory repositories
- Laboratory systems
- Internal knowledge bases
- APIs
- Approved external information sources
This is particularly important for pharma because transformation cannot realistically mean throwing away every existing system.
The objective is to make the existing ecosystem more intelligent.
3. Workflows — where intelligence becomes operations
This is the heart of the architecture.
An AI agent answering one question is useful.
An AI workflow completing a controlled business process is much more powerful.
A workflow can determine:
- What needs to happen
- Which data should be accessed
- Which specialist agents should participate
- In what sequence they should operate
- What validation should occur
- When a human should review the work
- What happens if the output fails a quality gate
- What needs to be recorded
- What final output should be produced
In other words:
Agents provide intelligence. Workflows provide operational intelligence.
Anxya's current platform describes workflows as multi-agent orchestrated processes with human-in-the-loop compliance gates.
That distinction is crucial for regulated industries.
4. APIs — turning workflows into infrastructure
Once a workflow exists, it does not necessarily have to remain inside a user interface.
It can become a reusable capability.
APIs allow organizations to expose approved AI capabilities to other applications, portals, enterprise systems or custom solutions.
For example:
A CRM could trigger a Medical Information workflow.
A safety system could trigger an adverse-event processing workflow.
A clinical-development application could trigger an evidence-synthesis workflow.
A regulatory platform could trigger a submission-readiness workflow.
The workflow therefore becomes an enterprise service, rather than merely a chatbot experience.
5. Agents — the intelligence users interact with
The final layer is the agent.
An agent may specialize in a particular domain or activity:
- Medical information
- Pharmacovigilance
- Regulatory affairs
- Clinical research
- Medical affairs
- Market access
- Evidence generation
- Competitive intelligence
- Quality
- Manufacturing
- Scientific research
An organization can therefore combine multiple specialist agents rather than expecting one general-purpose AI to perform every task.
This is particularly valuable in pharma because different activities require different evidence, reasoning patterns, controls and expertise.
Anxya currently describes its marketplace as containing domain-specialized agents and multi-agent pipelines across healthcare and life sciences.
The real power: organizations can create their own workflows
The most important capability is not simply selecting a pre-built workflow.
It is being able to create a workflow specific to the organization's way of working.
Consider a pharmaceutical company preparing a medical evidence briefing.
A conventional approach might require several people to manually:
- Search literature
- Review publications
- Extract evidence
- Compare findings
- Identify gaps
- Draft a briefing
- Verify references
- Review compliance
- Obtain approval
- Publish the final document
A custom AI workflow could orchestrate these activities.
For example:
Step 1 — Evidence retrieval
An evidence agent searches approved sources.
↓
Step 2 — Evidence extraction
A scientific agent identifies relevant findings.
↓
Step 3 — Evidence synthesis
A synthesis agent compares the evidence and identifies themes.
↓
Step 4 — Medical review
A medical agent evaluates scientific relevance and limitations.
↓
Step 5 — Compliance review
A compliance-oriented agent checks the output against predefined rules.
↓
Step 6 — Human approval
A designated medical or regulatory professional reviews the result.
↓
Step 7 — Final generation
The system produces the approved briefing.
↓
Step 8 — Audit trail
The workflow records what happened, which sources were used, which agents participated and where human approval occurred.
The important transformation is that the organization is no longer merely asking AI to write something.
It is designing a controlled digital process.
A pharmaceutical organization could build hundreds of these processes
Imagine a pharma organization creating its own workflow library.
Research & Discovery
Target intelligence workflow
Literature → scientific agents → competitive intelligence → evidence synthesis → scientist review → intelligence report
Compound research workflow
Research data → scientific analysis → literature evidence → safety signals → researcher review → research summary
Clinical Development
Clinical trial intelligence workflow
Trial data → protocol information → literature → analytics agent → clinical-development agent → insights → human review
Protocol review workflow
Protocol → specialist agents → eligibility analysis → operational assessment → statistical considerations → compliance review → reviewer approval
Pharmacovigilance
Safety case workflow
Case intake → information extraction → duplicate assessment → coding → medical assessment → narrative generation → quality review → human approval
The workflow can be designed so that AI performs appropriate preparation and analysis while designated professionals retain responsibility for decisions requiring expert judgment.
Medical Affairs
Scientific response workflow
Question → evidence retrieval → literature analysis → medical reasoning → reference verification → compliance check → medical approval → response
This is one of the clearest examples of where workflow orchestration can outperform a simple chatbot.
The organization is not merely generating an answer.
It is creating a repeatable, governed process for generating an answer.
Regulatory Affairs
Regulatory intelligence workflow
Regulatory sources → change detection → interpretation → impact analysis → product mapping → regulatory review → notification
Instead of people periodically checking dozens of sources manually, the workflow can continuously monitor approved information sources and escalate relevant changes.
Market Access
Payer evidence workflow
Evidence sources → clinical outcomes → economic evidence → payer requirements → evidence synthesis → market-access analysis → human review
The result is not simply a document.
It is an orchestrated evidence process.
Commercial & Competitive Intelligence
Competitor monitoring workflow
Approved sources → competitor detection → product/event classification → market analysis → strategic interpretation → confidence check → executive briefing
This can transform competitive intelligence from a periodic report into an ongoing organizational capability.
Quality
SOP review workflow
SOP repository → policy extraction → regulatory comparison → gap identification → quality review → remediation recommendations → approval
The same orchestration principle can be applied across quality systems, provided the workflow's intended use, validation requirements and human controls are appropriately designed.
The most important concept: human-in-the-loop orchestration
In regulated industries, automation should not mean removing humans from every decision.
It should mean putting humans where they create the most value.
A well-designed workflow can automate:
- Retrieval
- Classification
- Extraction
- Summarization
- Comparison
- Drafting
- Cross-checking
- Routing
- Notifications
- Documentation
- Repetitive quality checks
while reserving defined decision points for:
- Medical review
- Scientific judgment
- Regulatory interpretation
- Quality approval
- Safety assessment
- Final authorization
This creates a much more practical model:
AI does the preparation. AI performs the orchestration. Humans provide accountable judgment.
Anxya's architecture explicitly incorporates human-in-the-loop gates and audit-ready execution as part of its workflow model.
From "AI assistant" to "AI operating process"
This represents a fundamental change in how pharmaceutical organizations should think about AI.
The first generation of enterprise AI focused on:
"Ask the AI a question."
The next generation focuses on:
"Give the AI a task."
The emerging model is:
"Give the AI a governed process."
That difference is enormous.
A chatbot produces an answer.
An agent performs an activity.
A workflow coordinates activities.
A platform connects workflows to enterprise data and systems.
Together, they create an AI operating layer for the organization.
Why custom workflows matter
Every pharmaceutical organization has processes that are unique.
Two companies may both conduct pharmacovigilance, but their:
- SOPs
- approval structures
- data sources
- organizational responsibilities
- escalation rules
- terminology
- risk thresholds
- documentation requirements
- technology environments
may be different.
Therefore, the future cannot simply be a marketplace where everyone uses exactly the same workflow.
The real opportunity is:
Start with a proven workflow → customize it → connect your enterprise data → add your organization's rules → introduce approval gates → deploy it.
That creates a workflow that reflects how the organization actually operates.
Workflow composition: building with reusable intelligence
Another major advantage of the model is reusability.
Suppose an organization already has:
- A literature-search agent
- A medical-evidence agent
- A regulatory-check agent
- A citation-verification agent
- A document-generation agent
Those capabilities do not need to be rebuilt every time.
They can become reusable components.
One organization might compose them into:
Medical Affairs Evidence Workflow
Another into:
Regulatory Intelligence Workflow
Another into:
Clinical Development Briefing Workflow
The same intelligence can therefore participate in multiple business processes.
This is where an AI platform starts behaving more like an enterprise operating system than a collection of AI tools.
The business benefits for pharma
1. Faster execution
Processes that previously required multiple manual handoffs can be orchestrated automatically.
The goal is not simply faster AI generation.
It is faster end-to-end work.
2. Reduced operational friction
Instead of employees moving information between applications, people can interact with an orchestrated process.
Less copying.
Less searching.
Less repetitive drafting.
Less manual routing.
3. Greater consistency
A standardized workflow can enforce the same sequence of activities, validation checks and approval gates every time.
This can reduce process variability.
4. Better use of expert time
Scientists, physicians, regulatory professionals and quality experts should spend less time performing repetitive information-processing tasks.
Their time can be concentrated on interpretation, judgment and decisions.
5. Reusable organizational knowledge
When workflows encode an organization's processes, expertise becomes more reusable.
A high-performing process does not remain trapped inside one person's inbox or spreadsheet.
It can become an organizational capability.
6. Improved traceability
For regulated organizations, knowing how an output was produced is often as important as the output itself.
A well-designed workflow can capture:
- Inputs
- Data sources
- Agents used
- Processing steps
- Human interventions
- Approvals
- Outputs
- Exceptions
- Timestamps
- Version information
This creates a much stronger foundation for governance and auditability.
Anxya states that its platform is designed around evidence-cited outputs, audit-ready logs and human-in-the-loop controls.
Compliance should be designed into the workflow
AI governance cannot simply be added at the end.
For pharmaceutical workflows, controls should be considered at design time.
For example:
Who can initiate the workflow?
↓
Which data can it access?
↓
Which agents can operate on that data?
↓
What decisions can AI make?
↓
Which decisions require human approval?
↓
What evidence must be retained?
↓
What happens when confidence is insufficient?
↓
What must be logged?
↓
How is the final output approved?
This is particularly important when workflows intersect with GxP environments or regulated records.
Anxya's Trust Center appropriately distinguishes between alignment with frameworks and formal certification, noting that the platform itself should not be treated as automatically making a customer's workflow compliant or validated.
That distinction is important.
Technology can provide controls and capabilities. The organization remains responsible for validating and governing its intended use.
Building a custom workflow: a practical framework
A pharmaceutical organization can start with five questions.
1. What process are we trying to improve?
Do not begin with:
"Where can we use AI?"
Begin with:
"Which business process has the greatest combination of repetitive work, information complexity and decision-support potential?"
2. What information does the process require?
Map:
- Internal data
- External evidence
- Structured data
- Unstructured documents
- APIs
- Enterprise applications
3. Which activities should become agents?
Break the process into specialist tasks.
For example:
Retrieve → Extract → Analyze → Validate → Draft → Review → Approve
Each activity can potentially become an agent or an automated workflow step.
4. Where must humans remain accountable?
Explicitly define the human gates.
Do not leave this ambiguous.
For example:
AI analysis → Medical review → Regulatory approval
5. What must be recorded?
Define the audit and governance requirements before deploying the workflow.
This includes inputs, outputs, decisions, approvals, exceptions and versions.
The future: every pharma organization can have its own AI workflow layer
The strategic opportunity is larger than individual AI applications.
Imagine a pharmaceutical company with a digital workflow library containing:
500+ organizational processes
covering:
Research Clinical Development Medical Affairs Pharmacovigilance Regulatory Affairs Quality Manufacturing Market Access Commercial Corporate Functions
Each workflow can use shared agents, shared connectors, shared APIs and approved organizational data.
Instead of buying another disconnected AI application for every department, the organization can progressively build an AI-native operating layer across the enterprise.
That is the promise of workflow orchestration.
From marketplace to enterprise intelligence
A marketplace provides the starting point.
Organizations can select a ready-made workflow rather than starting from a blank page.
But the real value emerges when they customize it.
Discover → Copy → Customize → Connect → Govern → Test → Approve → Deploy → Monitor → Improve
This creates a continuous improvement loop.
A workflow becomes better as the organization learns:
- Which steps are useful
- Where humans intervene
- Where errors occur
- Which agents perform best
- Which sources provide better evidence
- Where additional controls are needed
- Which parts can safely be automated
The workflow therefore becomes a living organizational capability.
The bigger shift
Pharma has spent decades building systems of record.
The next transformation is building systems of action.
Systems of record store information.
AI agents interpret information.
Workflows coordinate actions.
Human experts govern decisions.
APIs connect capabilities.
And data provides the foundation.
This is why the five-layer architecture matters.
Data provides the knowledge.
Connectors provide access.
Workflows provide orchestration.
APIs provide programmability.
Agents provide intelligence.
Together, they create something much more powerful than a chatbot:
An intelligent, governed operating layer for pharmaceutical work.
The future of AI in pharma will not be determined by who has the most impressive chatbot.
It will be determined by who can turn the organization's most important processes into "trusted, reusable, measurable and continuously improving workflows.
And that is where custom workflow orchestration becomes one of the most important building blocks of the AI-native pharmaceutical enterprise.